Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study

Table 2 Patient characteristics

No. of patients	31
Male	26
Female	5
Median age (range)	65 (41-82) yr
WHO performance status
0	12
1	19
Positive hepatitis status
Hepatitis B	3
Hepatitis C	28
AFP > ULN
Yes	22
No	9
Child–Pugh status
A	14
B	17
Disease stage at study entry (TNM)
III C	15
IV	16
Grading (AJCC) at initial diagnosis
Well-differentiated	15
Moderately-well-differentiated	10
Poorly differentiated	6
Prior treatment
Chemoembolization	15
Local alcholization	6
Local radiofrequency	5
None	10

Data are expressed as median (range) or n. WHO: World Health Organization. ULN: Upper limit of normal; AJCC: American Joint Committee on Cancer.